Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan + Chlorthalidone vs Olmesartan + Hydrochlorothiazide in essential hypertension
NCT02493322Phase 3Withdrawn
- Sponsor
- EMS
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of chlorthalidone in essential hypertension, sponsored by EMS. Status: withdrawn.
02
Drugs
chlorthalidone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02493322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493322.